mTOR inhibitors in pediatric kidney transplantation

Pediatric Nephrology

Volumn 29, Issue 7, 2014, Pages 1119-1129

  Pape, Lars ^a   Ahlenstiel, Thurid ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Everolimus; mTOR inhibitors; Pediatric kidney transplantation; Sirolimus; Survival

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DASATINIB; DEFERASIROX; DENOSUMAB; EFAVIRENZ; EVEROLIMUS; HYPERICUM PERFORATUM EXTRACT; IMMUNOSUPPRESSIVE AGENT; IVACAFTOR; LEFLUNOMIDE; LUTEINIZING HORMONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MIFEPRISTONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PIMECROLIMUS; PREDNISOLONE; RAPAMYCIN; ROFLUMILAST; STEROID; TACROLIMUS; TESTOSTERONE; THYMOCYTE ANTIBODY; TOFACITINIB; TRASTUZUMAB; UNINDEXED DRUG; SEX HORMONE; TARGET OF RAPAMYCIN KINASE;

ACNE; ADAPTIVE IMMUNITY; ANEMIA; APHTHOUS ULCER; BLEEDING; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG MECHANISM; ECHINACEA; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHEDEMA; MAINTENANCE THERAPY; NAIL DISEASE; PARONYCHIA; PEDIATRIC SURGERY; POSTOPERATIVE CARE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS INFECTION; WOUND HEALING IMPAIRMENT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHILD; CYTOMEGALOVIRUS INFECTIONS; DRUG APPROVAL; DRUG EFFECTS; GRAFT REJECTION; LYMPHOPROLIFERATIVE DISORDERS; WOUND HEALING;

ANIMALS; CALCINEURIN INHIBITORS; CHILD; CYTOMEGALOVIRUS INFECTIONS; DRUG APPROVAL; GONADAL STEROID HORMONES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; SIROLIMUS; TOR SERINE-THREONINE KINASES; WOUND HEALING;

EID: 84901671866     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2505-9     Document Type: Review

References (92)

1. Joosten SA, Sijpkens YW, van Kooten C, Paul LC (2005) Chronic renal allograft rejection: Pathophysiologic considerations. Kidney Int 68:1-13 (Pubitemid 43181359)
2. Offner G, Toenshoff B, Hocker B, Krauss M, Bulla M, Cochat P, Fehrenbach H, Fischer W, Foulard M, Hoppe B, Hoyer PF, Jungraithmayr TC, Klaus G, Latta K, Leichter H, Mihatsch MJ, Misselwitz J, Montoya C, Muller-Wiefel DE, Neuhaus TJ, Pape L, Querfeld U, Plank C, Schwarke D, Wygoda S, Zimmerhackl LB (2008) Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. Transplantation 86:1241-1248
3. North American Pediatric Renal Trials and Collaborative Studies (2011) Annual dialysis report. Available at: https://Web.emmes.com/study/ped/annlrept/ annualrept2011.pdf
4. Grenda R, Watson A, Trompeter R, Tonshoff B, Jaray J, Fitzpatrick M, Murer L, Vondrak K, Maxwell H, van Damme-Lombaerts R, Loirat C, Mor E, Cochat P, Milford DV, Brown M, Webb NJ (2010) A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: The TWIST study. Am J Transplant 10:828-836
5. Cole OJ, Shehata M, Rigg KM (1998) Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 30:2200-2203 (Pubitemid 28399476)
6. Schuurman HJ, Pally C, Weckbecker G, Schuler W, Bruns C (1999) SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 31:1024-1025 (Pubitemid 29127790)
7. Matsumoto Y, Hof A, Baumlin Y, Muller M, Hof RP (2004) Differential effects of everolimus and cyclosporine A on intimal alpha-actin-positive cell dynamics of carotid allografts in mice. Transplantation 78:345-351 (Pubitemid 39095399)
8. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671-688 (Pubitemid 44151605)
9. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ (2007) Potential therapeutic applications of autophagy. Nat Rev Drug Discov 6:304-312 (Pubitemid 46505881)
10. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR (2004) mTOR inhibition reverses akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594-601 (Pubitemid 38796850)
11. Hartford CM, Ratain MJ (2007) Rapamycin: Something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 82:381-388 (Pubitemid 47414349)
12. Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A (2007) Proliferation signal inhibitors in transplantation: Questions at the cutting edge of everolimus therapy. Transplant Proc 39:2937 -2950
13. Gaumann A, Schlitt HJ, Geissler EK (2008) Immunosuppression and tumor development in organ transplant recipients: The emerging dualistic role of rapamycin. Transpl Int 21:207-217 (Pubitemid 351216959)
14. Gupta P, Kaufman S, Fishbein TM (2005) Sirolimus for solid organ transplantation in children. Pediatr Transplant 9:269-276 (Pubitemid 40780355)
15. Hymes LC, Warshaw BL (2005) Sirolimus in pediatric patients: Results in the first 6 months post-renal transplant. Pediatr Transplant 9:520-522 (Pubitemid 41153274)
16. Ettenger RB, Grimm EM (2001) Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 38:S22-S28 (Pubitemid 32916886)
17. Pape L, Ahlenstiel T, Ehrich JH, Offner G (2007) Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplant 11:291-295 (Pubitemid 46570146)
18. Federal Drug Administration. Available at: http://www.acessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm. Accessed 25 Apr 2013
19. European Medicines Agency. Available at: http://www.emea.europa.eu/ema/ index.jsp?curl=pages/medicines/landing/epar-search.jsp&mid= WC0b01ac058001d123. Accessed 25 Apr 2013
20. Garcia CD, Bittencourt VB, Alves AB, Garcia VD, Tumelero A, Antonello JS, Malheiros D (2006) Conversion to sirolimus in pediatric renal transplantation recipients. Transplant Proc 38:1901-1903 (Pubitemid 44190076)
21. Vilalta R, Vila A, Nieto J, Callis L (2003) Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation. Transplant Proc 35:703-704 (Pubitemid 36338123)
22. MacDonald AS (2003) Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 35:201S-208S
23. Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C (2006) Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 10:565-569
24. Ibanez JP, Monteverde ML, Diaz MA, Goldberg J, Turconi AF (2007) Sirolimus in chronic allograft nephropathy in pediatric recipients. Pediatr Transplant 11:777-780 (Pubitemid 47512321)
25. Hymes LC, Warshaw BL, Amaral SG, Greenbaum LA (2008) Tacrolimus withdrawal and conversion to sirolimus at three months post-pediatric renal transplantation. Pediatr Transplant 12:773 -777
26. Weintraub L, Li L, Kambham N, Alexander S, Concepcion W, Miller K, Wong C, Salvatierra O, Sarwal M (2008) Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation. Pediatr Transplant 12:541-549
27. Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM, Everolimus Pediatric Study Group (2008) Multicenter trial of everolimus in pediatric renal transplant recipients: Results at three year. Pediatr Transplant 12:456-463 (Pubitemid 351652075)
28. Pape L, Offner G, Kreuzer M, Froede K, Drube J, Kanzelmeyer N, Ehrich JH, Ahlenstiel T (2010) De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 10:2349-2354
29. Pape L, Lehner F, Blume C, Ahlenstiel T (2011) Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data. Transplantation 92:658-662
30. Schachter AD, Benfield MR, Wyatt RJ, Grimm PC, Fennell RS, Herrin JT, Lirenman DS, McDonald RA, Munoz-Arizpe R, Harmon WE (2006) Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. Pediatr Transplant 10:914-919 (Pubitemid 44683635)
31. El-Sabrout R, Delaney V, Qadir M, Butt F, Hanson P, Butt KM (2003) Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients - a single center experience. Transplant Proc 35:89S-94S (Pubitemid 36547922)
32. Ibanez JP, Monteverde ML, Goldberg J, Diaz MA, Turconi A (2005) Sirolimus in pediatric renal transplantation. Transplant Proc 37:682-684 (Pubitemid 40590669)
33. Iorember FM, Patel HP, Ohana A, Hayes JR, Mahan JD, Baker PB, Rajab A (2010) Steroid avoidance using sirolimus and cyclosporine in pediatric renal transplantation: One year analysis. Pediatr Transplant 14:93-99
34. Sindhi R (2003) Sirolimus in pediatric transplant recipients. Transplant Proc 35:113S-114S
35. Benfield MR, Bartosh S, Ikle D, Warshaw B, Bridges N, Morrison Y, Harmon W (2010) A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am J Transplant 10:81-88
36. Alvarez-Garcia O, Carbajo-Perez E, Garcia E, Gil H, Molinos I, Rodriguez J, Ordonez FA, Santos F (2007) Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol 22:954-961 (Pubitemid 46881913)
37. Sanchez CP, He YZ (2009) Bone growth during rapamycin therapy in young rats. BMC Pediatr 9:3
38. Rangel GA, Ariceta G (2009) Growth failure associated with sirolimus: Case report. Pediatr Nephrol 24:2047-2050
39. Hymes LC, Warshaw BL (2011) Linear growth in pediatric renal transplant recipients receiving sirolimus. Pediatr Transplant 15:570 -572
40. Gonzalez D, Garcia CD, Azocar M, Waller S, Alonso A, Ariceta G, Mejia N, Santos F (2011) Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol 26:961-966
41. Cavanaugh TM, Schoenemen H, Goebel J (2012) The impact of sirolimus on sex hormones in male adolescent kidney recipients. Pediatr Transplant 16:280-285
42. Tondolo V, Citterio F, Panocchia N, Nanni G, Favi E, Brescia A, Castagneto M (2005) Gonadal function and immunosuppressive therapy after renal transplantation. Transplant Proc 37:1915-1917 (Pubitemid 40790868)
43. Lee S, Coco M, Greenstein SM, Schechner RS, Tellis VA, Glicklich DG (2005) The effect of sirolimus on sex hormone levels of male renal transplant recipients. Clin Transplant 19:162-167 (Pubitemid 40424885)
44. Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L (2007) Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: An overview. Transpl Int 20:305-311
45. Kaczmarek I, Groetzner J, Adamidis I, Landwehr P, Mueller M, Vogeser M, Gerstorfer M, Uberfuhr P, Meiser B, Reichart B (2004) Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 4:1084-1088 (Pubitemid 38868598)
46. Rovira J, Diekmann F, Ramirez-Bajo MJ, Banon-Maneus E, Moya-Rull D, Campistol JM (2012) Sirolimus-associated testicular toxicity: Detrimental but reversible. Transplantation 93:874-879
47. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, Margreiter R, Hugo C, Grinyo JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF, ELITE-Symphony Study (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357:2562-2575 (Pubitemid 350294223)
48. Ekberg H, Bernasconi C, Tedesco-Silva H, Vitko S, Hugo C, Demirbas A, Acevedo RR, Grinyo J, Frei U, Vanrenterghem Y, Daloze P, Halloran P (2009) Calcineurin inhibitor minimization in the symphony study: Observational results 3 years after transplantation. Am J Transplant 9:1876-1885
49. Nashan B, Gaston R, Emery V, Saemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC (2012) Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 93:1075-1085
50. Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS (2011) Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: Pooled analysis of three clinical trials. Am J Transplant 11:2453-2462
51. Cullis B, D'Souza R, McCullagh P, Harries S, Nicholls A, Lee R, Bingham C (2006) Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 47:e67-e72
52. Pascual J (2007) Post-transplant lymphoproliferative disorder-the potential of proliferation signal inhibitors. Nephrol Dial Transplant 22[Suppl 1]:i27-i35
53. Zaltzman JS, Prasad R, Chun K, Jothy S (2005) Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus. Nephrol Dial Transplant 20:1748-1751 (Pubitemid 41418607)
54. Chiurchiu C, Carreno CA, Schiavelli R, Petrone H, Balaguer C, Trimarchi H, Pujol GS, Novoa P, Acosta F, Gonzalez C, Arriola M, Massari PU, Argentinian Registry of Everolimus Treated Renal Transplant Recipients (2010) Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. Transplant Proc 42:277-279
55. Jimenez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL (2004) Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 8:243 -248
56. Augustine JJ, Bodziak KA, Hricik DE (2007) Use of sirolimus in solid organ transplantation. Drugs 67:369-391 (Pubitemid 46425551)
57. Schachter AD, Meyers KE, Spaneas LD, Palmer JA, Salmanullah M, Baluarte J, Brayman KL, Harmon WE (2004) Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 8:171-177 (Pubitemid 38508429)
58. Powell HR, Kara T, Jones CL (2007) Early experience with conversion to sirolimus in a pediatric renal transplant population. Pediatr Nephrol 22:1773 -1777
59. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L (2005) Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20:2517-2523 (Pubitemid 41548881)
60. Butani L (2004) Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 78:1362-1366
61. Letavernier E, Bruneval P, Vandermeersch S, Perez J, Mandet C, Belair MF, Haymann JP, Legendre C, Baud L (2009) Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 24:630-638
62. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8:128-135 (Pubitemid 34155123)
63. Oroszlan M, Bieri M, Ligeti N, Farkas A, Meier B, Marti HP, Mohacsi P (2010) Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 23:125-132
64. Valente JF, Hricik D, Weigel K, Seaman D, Knauss T, Siegel CT, Bodziak K, Schulak JA (2003) Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 3:1128-1134 (Pubitemid 37064553)
65. Dean PG, Lund WJ, Larson TS, Prieto M, Nyberg SL, Ishitani MB, Kremers WK, Stegall MD (2004) Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77:1555-1561 (Pubitemid 38703037)
66. Nashan B, Citterio F (2012) Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: A critical review of the literature. Transplantation 94:547 -561
67. Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, Wuthrich RP, Scheidl S, May C, Paulus EM, Muhlfeld A, Wolters HH, Pressmar K, Stahl R, Witzke O, ZEUS Study Investigators (2012) Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Am J Transplant 12:1528-1540
68. Van Damme-Lombaerts R, Webb NA, Hoyer PF, Mahan J, Lemire J, Ettenger R, McMahon L, Cambon N, Boger R, Kovarik JM (2002) Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. Pediatr Transplant 6:147-152 (Pubitemid 34493036)
69. Zimmerman JJ, Kahan BD (1997) Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 37:405-415 (Pubitemid 27215068)
70. Schubert M, Venkataramanan R, Holt DW, Shaw LM, McGhee W, Reyes J, Webber S, Sindhi R (2004) Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 4:767-773 (Pubitemid 38637576)
71. Venkataramanan R, Sindhi R (2006) Sirolimus pharmacokinetic differences between children and adults. Pediatr Transplant 10:872 -874
72. Grimm EM, Kelley PA, Seinford RD, Gitomer JJ, Kahan BD (2000) Sirolimus pharmacokinetics in pediatric renal transplants. Pediatr Transplant 4:S86a
73. Zimmerman JJ, Harper D, Getsy J, Jusko WJ (2003) Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol 43:1168-1176 (Pubitemid 37174449)
74. Vu MD, Qi S, Xu D, Wu J, Fitzsimmons WE, Sehgal SN, Dumont L, Busque S, Daloze P, Chen H (1997) Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 64:1853-1856 (Pubitemid 28041730)
75. Brandhorst G, Tenderich G, Zittermann A, Oezpeker C, Koerfer R, Oellerich M, Armstrong VW (2008) Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit 30:113-116 (Pubitemid 351161109)
76. Pascual J, del Castillo D, Cabello M, Pallardo L, Grinyo JM, Fernandez AM, Brunet M (2010) Interaction between everolimus and tacrolimus in renal transplant recipients: A pharmacokinetic controlled trial. Transplantation 89:994-1000
77. Marin-Casino M, Crespo M, Mateu-de Antonio J, Pascual J (2011) Monitoring sirolimus levels: How does it affect the immunoassay used? Nefrologia 31:359 -361
78. Coentrao L, Carvalho C, Sampaio S, Oliveira JG, Pestana MI (2010) Relationship between everolimus blood concentration assessed using the innofluor certican fluorescence polarization immunoassay and the architect i system sirolimus chemiluminescent microparticle immunoassay. Transplant Proc 42:1867-1869
79. Katzman SD, O'Gorman WE, Villarino AV, Gallo E, Friedman RS, Krummel MF, Nolan GP, Abbas AK (2010) Duration of antigen receptor signaling determines T-cell tolerance or activation. Proc Natl Acad Sci USA 107:18085-18090
80. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, Powell JD (2011) The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 12:295-303
81. Thomson AW, TurnquistHR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9:324-337
82. Yang K, Neale G, Green DR, He W, Chi H (2011) The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat Immunol 12:888-897
83. Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, Altuntas CZ, Sass Bak-Jensen K, McGeachy MJ, Do JS, Xiao H, Delgoffe GM, Min B, Powell JD, Tuohy VK, Cua DJ, Li X (2010) The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 32:54-66
84. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD (2009) The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30:832-844
85. Battaglia M, Stabilini A, Tresoldi E (2012) Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. Methods Mol Biol 821:279- 293
86. Brouard S, Puig-Pey I, Lozano JJ, Pallier A, Braud C, Giral M, Guillet M, Londono MC, Oppenheimer F, Campistol JM, Soulillou JP, Sanchez-Fueyo A (2010) Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy. Am J Transplant 10:2604-2614
87. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R (2009) mTOR regulates memory CD8 T-cell differentiation. Nature 460:108-112
88. Araki K, Youngblood B, Ahmed R (2010) The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev 235:234-243
89. Pascual J, Boletis IN, Campistol JM (2006) Everolimus (certican) in renal transplantation: A review of clinical trial data, current usage, and future directions. Transplant Rev (Orlando) 20:1-18
90. Zuckermann A, Manito N, Epailly E, Fiane A, Bara C, Delgado JF, Lehmkuhl H, Ross H, Eisen H, Chapman J, Valantine H (2008) Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 27:141-149 (Pubitemid 351221042)
91. Lexicomp (2013) Lexicomp Online™. Available at: http://www.uptodate.com/contents/everolimus-drug-information?source= search-result&search=everolimus&selectedTitle=1%7E80#F7710406. Lexi-Drugs Online™, Lexicomp Inc., Hudson. Accessed 25 Apr 2013
92. Lexicomp (2013) Lexicomp Online™. Available at: http://www.uptodate.com/contents/sirolimus-drug-information?source= search-result&search=sirolimus&selectedTitle=1%7E150#F221195. Lexi-Drugs Online™, Lexicomp, Inc., Hudson. Accessed 25 Apr 2013